Israeli Start-Up Alcobra Develops New Treatment for Attention Deficit Disorder

December 2, 2013 3:26 pm 2 comments
Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israeli pharmaceutical start-up Alcobra Pharmaceuticals is listed on the NASDAQ electronic stock exchange under the ticker ADHD, the disease it treats with a non-stimulant compound that is expected to come to the market in 2015.

In an interview with Israeli business daily Globes, CEO Dr. Yaron Daniely explained how the company was originally created in 2008 to develop the molecule metadoxine to help inhibit the effects of alcohol on the brain.

“The goal was to create a pill that would quickly reduce blood alcohol levels, so that people would be able to drive safely,” explains Daniely. “It turned out the drug had no significant impact on removing alcohol from the blood, but it had a very significant impact on cognitive ability. In driving, memory, and attention tests that were conducted, it was as though those people were not drunk, despite the fact that, in terms of the amount of alcohol in their blood, it was not clear that they would be able to stand on their own two feet. So the idea to treat Attention Deficit Disorder came about.”

A pilot the company conducted in 2010 among 40 adults with ADHD showed “an immediate and significant improvement in attention tests. As a result of this, the company reinvented itself,” Daniely said, which is when he was named by researchers Dr. Dalia Megiddo and Udi Gilboa to be its new CEO.

Bilingual with a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine, an NIH Visiting Fellow in Cell Biology, a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science, in Rehovot, and an MBA from the Technion – Israel Institute of Technology, Daniely also was VP Business Development at Gamida Cell Ltd., managing its joint venture with Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) to develop a cancer drug.

The idea was to approach TEVA to fund the start-up, which it did with $5 million to fund its first tests. But with TEVA later in a management crisis, and its options to increase its position in Alcobra expired, the team sought an IPO on the NASDAQ, which has since net it some $60 million in proceeds and a market capitalization of $220 million, more than enough to fund its final tests and market launch.

Daniely said the chemical compound metadoxine has been approved for 40 years for the treatment of liver disease in third-world countries, including India, China, Russia, and Thailand. The company has registered a patent for the use of metadoxine for neurological conditions, through a timed-release of the substance, so its effect on the patient lasts a few hours.

Globes said that Alcobra has no labs, its raw materials are manufactured by a third party in Germany, and the pills themselves are manufactured in the US. The company believes that the drug combines the benefits of the two existing classes of ADHD drugs – the stimulants, such as Ritalin and Concerta, and the non-stimulant drugs, such as Strattera – and claims that it does not have their drawbacks.

According to the company, the results of the clinical trials showed that the drug is not addictive, worked faster and was twice as effective as the existing non-stimulant drugs, and had a similar anti-ADHD effect to that of the stimulants. It primarily affects cognitive ability, less so hyperactivity.

Daniely advised other Israeli start-ups to follow four lessons from Alcobra’s successful IPO. “The first element was quality, and a refusal to compromise,” he said. “Alcobra, from day one, tried to be different from other companies. We have an almost pedantic stubbornness not to do things too small or too short, but rather to do the things the way we would if we were a company in Silicon Valley. Therefore, our Phase II trial didn’t include 20 people over two weeks, instead, it included 120 people, with a placebo control, over the course of six weeks, using the exact same measures that all the ADHD drugs in the world are measured by. Many companies understand too late that they are conducting poorer trials without the appropriate controls.”

The second element was the company’s target market. “There’s nothing like ADHD,” he says. “First of all, people understand the market; there are drugs, it is known how much each company is selling and why, there are patients, there is a market that turns over $4 billion each year in the US. Also, people think they understand what ADHD is. It affects almost everyone, their kid, or their nephew.”

A third element is the pace of development: “With ADHD, unlike rare cancers, participants for clinical trials are incredibly easy to find. So our time to market and our ability to build our development process are such that almost every month we have good news for shareholders. The phase III trial will include 300 patients, in 20 medical centers, over the course of six months.”

The fourth element that helped secure funding was his native-English speaking ability, personal CV and track record and a decision to invite well-known professionals from the ADHD research community to be on their team, in this case, Prof. Lenard Adler, a researcher from NYU and an expert in ADHD drug development, who serves as head of the clinical committee that advises the company. “When someone like him sits next to you and says: ‘I conducted the trial and I stand behind the results,’ they can’t blow you off. Israeli entrepreneurs need to understand this and bring these people to their companies, so they can bridge the gap,” Daniely said.

While the company tried to get funding in Israel, where ADHD is less frequently diagnosed, its success in raising money on the NASDAQ has led many other young pharma companies to its doors, seeking advice. Its success has also led to new projects.

“Many things happened at the company, and our ability to implement plans grew. We had a tremendous opportunity to treat fragile X syndrome, which is associated with autism. It is a very common condition, which is very difficult for many who suffer from it, and there is no treatment. In a trial we conducted on animals with a kind of fragile X, we came up with outstanding results. It completely normalized learning, memory, social behavior, and communication. In parallel, the market in the US was still on fire, and said, ‘go, secure the investment, and bring in more cash,’” Daniely said.

The funds Alcobra raised guarantee that the company will have full funding until it is approved as a drug for adult ADHD, which, according to Daniely, is expected to reach market in late 2015, and for children soon afterwards. The money will also fund the fragile X trial.

2 Comments

  • In this period of financial crisis, you usually do not have to spend huge amount of money just to find out girls
    get their clothes off in front individuals. You have to discover once the nude models from the sex chat website can be extremely beautiful and
    deliciously attractive. Military husbands stationed in the Middle
    East have been in a position to witness the birth of an youngster through webcams.

  • Davida Rosenberg

    Please update me when this will be available in the U.S.
    A family member age 36 male.. has suffered his whole young life with this condition.

Leave a Reply

Please note: comments may be published in the Algemeiner print edition.


Current day month ye@r *

More...

  • Arts and Culture US & Canada Israeli Actress Gal Gadot in Talks to Star in Ben-Hur Remake

    Israeli Actress Gal Gadot in Talks to Star in Ben-Hur Remake

    Israeli actress Gal Gadot is in negotiations to take on the female lead role in the remake of the 1959 classic Ben-Hur, according to The Hollywood Reporter. If the deal is finalized Gadot will play Esther, a slave and Ben-Hur’s love interest. Actor Jack Huston will star as the Jewish prince who is betrayed into slavery by his childhood friend Messala, played by Toby Kebbell. Ben-Hur fights for his freedom and vengeance with the help of Morgan Freeman’s character, who trains Ben-Hur how to win at chariot-racing. [...]

    Read more →
  • Jewish Identity Sports Young Israelis Try to Crowd-Fund Their Way to Major League Baseball Playoffs

    Young Israelis Try to Crowd-Fund Their Way to Major League Baseball Playoffs

    JNS.org – Baseball, hot dogs, and apple pie are the American dream. So why do two young men who have built their lives in Israel have a GoFundMe crowd-funding webpage with the urgent message that they need $3,000 to travel to the U.S. to watch the Kansas City Royals and Baltimore Orioles square off for Major League Baseball’s (MLB) American League championship? Brothers Naftali and Yoni Schwartz, 27 and 25, respectively, are Kansas City natives. Even though they made aliyah with their [...]

    Read more →
  • Blogs Sports Race Cars Speed Through Jerusalem in Amazing Exhibition

    Race Cars Speed Through Jerusalem in Amazing Exhibition

    Some 3,000 years ago, King David probably never imagined cars racing at 240 kilometers per hour (150 miles per hour) through the ancient capital of the Jewish people. But on Monday and Tuesday, October 6-7, thousands of Israelis lined the streets to watch Porsche, Audi, and Ferrari race cars fly through the capital against the backdrop of the Tower of David, the Old City Walls, and other city landmarks. The second annual non-competitive Jerusalem Formula One Road Show had been [...]

    Read more →
  • Israel Sports NBA Superstar LeBron James Says He Wants to Visit Israel

    NBA Superstar LeBron James Says He Wants to Visit Israel

    Cleveland Cavaliers forward LeBron James expressed interest in visiting Israel someday, local news site Cleveland.com reported on Sunday. Speaking to Israeli reporters before the Cleveland Cavaliers’ preseason debut against Maccabi Tel Aviv, the NBA star said he had never visited the Jewish state but “I want to look forward to going there if I get an opportunity to.” When asked by an Israeli reporter if there was “any chance that LeBron James and Cleveland comes to Tel Aviv,” the athlete said [...]

    Read more →
  • Sports US & Canada Florida Rabbi Dominates Former Basketball Star Congressman in Hoops Showdown (VIDEO)

    Florida Rabbi Dominates Former Basketball Star Congressman in Hoops Showdown (VIDEO)

    A Florida-based Chabad rabbi put former basketball star, U.S. Congressman Curt Clawson to shame on the court when the two faced off one-on-one recently. A YouTube video, posted online on Tuesday, shows Rabbi Fishel Zaklos of Chabad of Naples shooting hoops with the Florida politician, who played basketball in high school and at Purdue University in Indiana. The game took place in the parking lot of the Chabad Jewish center run by Zaklos. During the 1-minute clip, Zaklos scores two impressive [...]

    Read more →
  • Sports US & Canada David Blatt’s Cleveland Cavaliers Rout Maccabi Tel Aviv, 107-80

    David Blatt’s Cleveland Cavaliers Rout Maccabi Tel Aviv, 107-80

    JNS.org – Less than five months after leading Maccabi Tel Aviv to its sixth European basketball title, David Blatt, now the head coach of the NBA’s Cleveland Cavaliers, routed his former team in an exhibition game on Sunday, with the Cavaliers dominating Maccabi 107-80 at the Quicken Loans Arena in Cleveland. The 20,562 fans in attendance witnessed Lebron James’s first appearance in a Cavaliers uniform since he left the club in free agency for the Miami Heat four years ago. [...]

    Read more →
  • Sports US & Canada Jewish New York Giants Guard Plans to Fast on Yom Kippur

    Jewish New York Giants Guard Plans to Fast on Yom Kippur

    New York Giants offensive guard Geoff Schwartz said on Wednesday that he will not eat anything between sundown Friday and sundown Saturday in observation of Yom Kippur, ESPN reported. “If I was playing, I wouldn’t fast, because I’ve got to be able to fuel myself to play,” said the Jewish athlete, who is on short-term leave due to a toe injury. “But it’s not that tough, really. I’ll eat dinner at 5:00 Friday, then I’ll go to services and I’ll just [...]

    Read more →
  • Book Reviews Personalities How a Jewish Leader With 3 Months to Live Created a ‘Seminar’ on Life

    How a Jewish Leader With 3 Months to Live Created a ‘Seminar’ on Life

    JNS.org – What would you do if you found out that you had only three more months to live? Gordon Zacks was a successful businessman, a leader of Jewish life, and a confidante and adviser to President George H.W. Bush. He knew that he had prostate cancer, but doctors advised him that it was very slow-growing and nothing to worry about. Then came the day when the doctors told him his cancer metastasized to his liver, and that he had [...]

    Read more →



Sign up now to receive our regular news briefs.